Search Results
Sep 01, 2026, 10:31 ET The Oral PCSK9 Inhibitor Market Enters High-Growth Phase Owing to the Approval of Merck's LIPFENDRA and the Emergence of Oral PCSK9 Inhibitor Drugs, Including, AstraZeneca's AZD0780, Aqur's AQR-008, and Others | DelveInsight
currently undergoing Phase III clinical development.Aqur Biosciences' AQR-008 employs a differentiated mechanism of action by targeting the EGF-A domain of the LDL receptor rather than directly inhibiting PCSK9. By preventing PCSK9 from binding to LDLR, AQR-008 is designed to protect the receptor
More news about: DelveInsight Business Research, LLP
Sep 01, 2026, 08:30 ET FibroBiologics Announces Issuance of New U.S. Patent for the Treatment of Degenerative Disc Disease Using Fibroblast Conditioned Media
antagonists such as naltrexone, stimulate fibroblasts to increase the production of regenerative growth factors, including epidermal growth factor (EGF). Conditioned media and other components derived from these stimulated fibroblasts may then be delivered to a patient, either directly into the disc
More news about: FibroBiologics, Inc.
Aug 27, 2026, 08:31 ET Piramal Pharma refuerza las operaciones preparadas para el futuro con una reducción del 22,6 % de las emisiones, un 41 % de energías renovables y cero observaciones de OAI de la FDA de EE. UU.
https://ppl-da-website-new-afd-endpoint-bgd4d0c9egf9g2eq.a01.azurefd.net/media/documents/PPL-Sustainability-Report-2025-26.pdf Acerca de Piramal Pharma LimitedPiramal Pharma Limited (PPL, NSE:
More news about: Piramal Pharma Limited
Aug 27, 2026, 07:51 ET Piramal Pharma rafforza le proprie attività operative rendendole a prova di futuro, grazie a una riduzione del 22,6% delle emissioni, al 41% di energia rinnovabile e a zero osservazioni classificate come OAI (Official Action Indicated) da parte della USFDA
https://ppl-da-website-new-afd-endpoint-bgd4d0c9egf9g2eq.a01.azurefd.net/media/documents/PPL-Sustainability-Report-2025-26.pdf Profilo di Piramal Pharma LimitedPiramal Pharma Limited (PPL,
More news about: Piramal Pharma Limited
Aug 27, 2026, 07:43 ET Piramal Pharma renforce ses opérations prêtes pour l'avenir avec une réduction de 22,6 % des émissions, 41 % des énergies renouvelables et « zéro observation » de l'OAI par la FDA américaine
https://ppl-da-website-new-afd-endpoint-bgd4d0c9egf9g2eq.a01.azurefd.net/media/documents/PPL-Sustainability-Report-2025-26.pdf À propos de Piramal Pharma LimitedPiramal Pharma Limited (PPL,
More news about: Piramal Pharma Limited
Aug 27, 2026, 07:36 ET Piramal Pharma、排出量22.6%削減、再生可能エネルギー比率41%、USFDAのOAI指摘ゼロで将来に備えた事業運営を強化
Committee）の監督下に置かれ、ESGへの配慮が長期的な事業パフォーマンスおよび価値創出に不可欠な要素であり続けるよう徹底しています。サステナビリティレポートはGRIスタンダードに準拠し、SASBおよびUNGCの枠組みに沿って作成されており、持続可能な成長、責任ある資本配分、実効性のあるステークホルダーエンゲージメントに対するPPLのコミットメントを明確に示しています。詳細については、以下で公開されている完全版レポートをご参照ください：https://ppl-da-website-new-afd-endpoint-bgd4d0c9egf9g2eq.a01.azurefd.net/media/documents/PPL-Sustainability-Report-2025-26.pdf Piramal
More news about: Piramal Pharma Limited
Aug 27, 2026, 07:21 ET Piramal Pharma stärkt zukunftsfähige Betriebsabläufe durch Emissionsreduktion von 22,6 %, Anteil erneuerbarer Energien von 41 % und null Beanstandungen im Rahmen des OAI-Verfahrens der US-Lebensmittelüberwachungs- und Arzneimittelbehörde (USFDA)
https://ppl-da-website-new-afd-endpoint-bgd4d0c9egf9g2eq.a01.azurefd.net/media/documents/PPL-Sustainability-Report-2025-26.pdf Über Piramal Pharma LimitedPiramal Pharma Limited (PPL, NSE: PPLPHARMA
More news about: Piramal Pharma Limited
Aug 26, 2026, 10:49 ET Piramal Pharma Strengthens Future Ready Operations with 22.6% Emissions Reduction, 41% Renewable Energy and Zero USFDA OAI Observations
https://ppl-da-website-new-afd-endpoint-bgd4d0c9egf9g2eq.a01.azurefd.net/media/documents/PPL-Sustainability-Report-2025-26.pdf About Piramal Pharma LimitedPiramal Pharma Limited (PPL, NSE:
More news about: Piramal Pharma Limited
Aug 26, 2026, 10:45 ET Piramal Pharma Strengthens Future Ready Operations with 22.6% Emissions Reduction, 41% Renewable Energy and Zero USFDA OAI Observations
https://ppl-da-website-new-afd-endpoint-bgd4d0c9egf9g2eq.a01.azurefd.net/media/documents/PPL-Sustainability-Report-2025-26.pdf About Piramal Pharma LimitedPiramal Pharma Limited (PPL, NSE:
More news about: Piramal Pharma Limited
Aug 20, 2026, 08:30 ET FibroBiologics Announces Australian Patent Accepted for Cannabidiol Adjuvant Therapy for the Treatment of Degenerative Disc Disease
the use of cannabidiol to enhance the regenerative activity of fibroblasts, including augmenting their production of growth factors such as IGF-1 and EGF-1."Degenerative disc disease affects an enormous number of people, and the treatments available today address symptoms rather than the disease
More news about: FibroBiologics, Inc.
Jul 08, 2026, 07:44 ET Il rapporto annuale di Piramal Pharma per l'esercizio finanziario 2026 mette in evidenza la portata globale dell'azienda, la sua crescita spinta dall'innovazione e i traguardi raggiunti in materia di sostenibilità
https://ppl-da-website-new-afd-endpoint-bgd4d0c9egf9g2eq.a01.azurefd.net/media/documents/Annual-Report-FY-2025-26.pdfInformazioni su Piramal Pharma LimitedPiramal Pharma Limited (PPL) (NSE:
More news about: Piramal Pharma Limited
Jul 08, 2026, 02:54 ET Der Geschäftsbericht von Piramal Pharma für das Geschäftsjahr 2026 unterstreicht die globale Reichweite, das innovationsgetriebene Wachstum und die Meilensteine im Bereich Nachhaltigkeit
https://ppl-da-website-new-afd-endpoint-bgd4d0c9egf9g2eq.a01.azurefd.net/media/documents/Annual-Report-FY-2025-26.pdfInformationen zu Piramal Pharma LimitedPiramal Pharma Limited (PPL, NSE:
More news about: Piramal Pharma Limited
Jul 08, 2026, 02:52 ET Piramal Pharmaの2026年度年次報告書、グローバル規模、イノベーション主導の成長、サステナビリティのマイルストーンを示す
詳細については、https://ppl-da-website-new-afd-endpoint-bgd4d0c9egf9g2eq.a01.azurefd.net/media/documents/Annual-Report-FY-2025-26.pdfで公開されている報告書全文をご参照ください。Piramal
More news about: Piramal Pharma Limited
Jul 08, 2026, 00:29 ET Le rapport annuel de Piramal Pharma pour l'exercice 2026 souligne l'envergure mondiale de la société, sa croissance axée sur l'innovation et ses avancées majeures en matière de développement durable
https://ppl-da-website-new-afd-endpoint-bgd4d0c9egf9g2eq.a01.azurefd.net/media/documents/Annual-Report-FY-2025-26.pdfÀ propos de Piramal Pharma LimitedPiramal Pharma Limited (PPL) (NSE: PPLPHARMA)
More news about: Piramal Pharma Limited
Jul 08, 2026, 00:20 ET El informe anual de Piramal Pharma del año fiscal 2026 destaca su alcance global
https://ppl-da-website-new-afd-endpoint-bgd4d0c9egf9g2eq.a01.azurefd.net/media/documents/Annual-Report-FY-2025-26.pdfAcerca de Piramal Pharma LimitedPiramal Pharma Limited (PPL) (NSE: PPLPHARMA)
More news about: Piramal Pharma Limited
Jul 07, 2026, 08:50 ET Piramal Pharma's FY2026 Annual Report showcases global scale, innovation-led growth and sustainability milestones
https://ppl-da-website-new-afd-endpoint-bgd4d0c9egf9g2eq.a01.azurefd.net/media/documents/Annual-Report-FY-2025-26.pdfAbout Piramal Pharma LimitedPiramal Pharma Limited (PPL, NSE: PPLPHARMA)
More news about: Piramal Pharma Limited
Jul 07, 2026, 08:36 ET Piramal Pharma's FY2026 Annual Report showcases global scale, innovation-led growth and sustainability milestones
https://ppl-da-website-new-afd-endpoint-bgd4d0c9egf9g2eq.a01.azurefd.net/media/documents/Annual-Report-FY-2025-26.pdfAbout Piramal Pharma LimitedPiramal Pharma Limited (PPL, NSE: PPLPHARMA)
More news about: Piramal Pharma Limited
Apr 30, 2026, 09:07 ET JASMINE Trial Demonstrates Prolacta's Human Milk-Based Fortifiers Deliver Superior Growth in Premature Infants While Maintaining Japan's Renowned Low NEC Rate
Tamar C, Greenfield K, McDonald K, Levy E, Brumbaugh JE, Knoop K. EGF and IgA in maternal milk, donor milk, and milk fortifiers in the neonatal intensive care unit setting. PLoS One. 2025;20(4):e0313465. doi:10.1371/journal.pone.0313465
More news about: Prolacta Bioscience
Apr 19, 2026, 20:15 ET CStone Presented Preclinical Data for Three Novel or Differentiated ADCs at AACR 2026, Including CS5007 (EGFR/HER3)
of J17 (the naked antibody of CS5007) across various human tumor cell lines under a continuous stimulation microenvironment simulated by ligands (TGF-α/EGF and/or NRG1 β1). By dually targeting EGFR and HER3, CS5007 achieves potent inhibition of downstream signaling cascades, including the Akt and MAPK
More news about: CStone Pharmaceuticals
Apr 09, 2026, 13:03 ET Where Champions Are Forged: FORGE Scholastic Esports Championship Returns May 15-17
The championship features top teams from leading scholastic esports organizations including EGF, ECAC, NECC, and SAMSAT's R20 Esports program battling across 11 fan-favorite titles:→ Overwatch 2, Rocket League, Super Smash
More news about: Rally Cry
Apr 07, 2026, 08:36 ET SMEG USA Elevates Daily Rituals with Chic Espresso and Cold Brew Coffee Machine and Multipurpose Grinder
Black finish is now available for its 1950s style 2-Slice Toaster (model TSF01), Electric Kettle (model KLF03), Semi-Automatic Espresso Machine (model EGF03), and Drip Coffee Machine (model DCF02). A crisp Matte White colorway has also been added for the Electric Kettle (model KLF03) and 2-Slice Toaster
More news about: SMEG USA
Mar 10, 2026, 12:46 ET From Competition to Career: Army National Guard and FORGE Redefine Scholastic Esports in 2026
opportunity.The championship will feature official competitions hosted in partnership with leading scholastic esports organizations, including ECAC, EGF, NECC, and SAMSAT's R20 Esports program, alongside activations from industry leaders Ubisoft and TwitchU.Beyond competition, the three-day event
More news about: Rally Cry
Feb 13, 2026, 06:15 ET Elkem ASA - Notice of extraordinary general meeting
https://mb.cision.com/Public/16930/4307452/a51f6979af0964f3.pdfElkem - Innkalling til EGF 9 mars 2026
More news about: Elkem
Feb 13, 2026, 06:13 ET Elkem ASA - Notice of extraordinary general meeting
https://mb.cision.com/Public/16930/4307452/a51f6979af0964f3.pdfElkem - Innkalling til EGF 9 mars 2026
More news about: Elkem
Feb 04, 2026, 06:30 ET Boston Scientific announces results for fourth quarter and full year 2025
device.Commenced enrollment in the OPTIMIZE clinical trial, which uses the Cortex OPTIMAP™ Electrographic Flow (EGF) Mapping Technology with the FARAPULSE™ PFA Platform to evaluate how EGF-guided mapping and delivery of PFA to atrial fibrillation (AF) sources outside the pulmonary veins impacts
More news about: Boston Scientific Corporation